Chimerix Inc. (CMRX) had a good day on the market for Wednesday September 25 as shares jumped 5.67% to close at $2.61. About 291,487 shares traded hands on 1,604 trades for the day, compared with an average daily volume of n/a shares out of a total float of 61.27 million. After opening the trading day at $2.48, shares of Chimerix Inc. stayed within a range of $2.65 to $2.47.
With today’s gains, Chimerix Inc. now has a market cap of $159.92 million. Shares of Chimerix Inc. have been trading within a range of $4.40 and $1.74 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Chimerix Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs. The company’s focus is on novel nucleosides with activity against influenza, norovirus, CMV, and BK virus, among others. It derives its revenue from two sources contracts and grants, and collaborations and licensing. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of DNA viruses, including smallpox, adenoviruses, and the human herpesviruses. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are currently available.
Chimerix Inc. is based out of Durham, NC and has some 40 employees. Its CEO is Michael Sherman.